medigraphic.com
ISSN 0210-5187 (Electronic)

2003, Number 3

<< Back Next >>

Med Cutan Iber Lat Am 2003; 31 (3)

Toxic Epidermal Necrolysis Inducided by Lamotrigine. Treatment with Intravenous Immunoglobulins

Gatti CF, Rodriguez MC, Cha DM, Barquín MA

Language: Spanish
References: 26
Page: 182-186
PDF size: 247.53 Kb.


ABSTRACT

Toxic epidermal necrolysis (TEN) is a rare and very severe cutaneo mucous disease. The most common ethiologic agents are different drugs administred either individually or jointly.
We are presenting the case of a 59- year-old woman who developed TEN two monthoras after the onset of treatment with lamotrigine and valproic acid. She was admitted in the intensive care unit, and was treated with intravenous human immunoglobulins. No progression of the condition was observed, and the patient experienced a good evolution.
We concluded that immunoglobulins are a new therapeutic option for TEN.


REFERENCES

  1. Schulz JT, Sheridan RL, Ryan CM, Mc Kool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204.

  2. Rougeau JC, Kelly JP, Naldi L, et al. Medicación use and the risk of Stevens- Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600-7.

  3. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000;18:485-95,ix.

  4. Bastuji-Garin S, Rzany, B Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993;129:92-6.

  5. Bastuji-Garin S, Fouchard N, Bertocci M, Roujeau JC, et al. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53. 185 Figura 3. Imagen a los 40 días con las lesiones cutáneas en franca regresión. Med Cutan Iber Lat Am 2003; 31(3): 182-186 46 Gatti F., et al. Necrólisis epidérmica tóxica inducida por lamotrigina. Tratamiento con inmunoglobulina intravenosa

  6. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive-Care-Med. 1997; 23:1237-44.

  7. García Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens- Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000;136:323-7.

  8. Palomo A, Rodriguez Gómez J, Guerrero E. Necrólisis epidérmica tóxica inducida por lamotrigina. Tratamiento con ciclosporina. Actas Dermosifilogr 1999;90:612-615.

  9. Bushman M, Brooke R, Hewitt- Symonds, M. Prolonged toxic epidermal necrolysis due to Lamotrigine. Clin. Exp. Dermatol. 2000;25:349-51.

  10. Bocquet H, Farmer M, Bresieux JM. Lyell syndrome and Stevens-Johnson syndrome caused by lamotrigine. Ann-dermatol-venerol.1999;126:46-8.

  11. Duval X, Chosidow O, Semah F, Lipsker D. Lamotrigine versus carbamazepine in epilepsy. Lancet 1995; 345:1301-2.

  12. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine- induced severe cutaneous adverse reactions. Epilepsia 1998;39 (Suppl 7):S22-6.

  13. Vukelic D, Bozinovic D, Tesovic G. Lamotrigine and toxic epidermal necrolysis. Dermatology. 1997;195:307.

  14. Rzanny B, Correia O, Kelly JP. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reactions. Lancet 1999;353:2190-4.

  15. Sullivan J R, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and inmunosupressive management. Australas JDermatol. 1996;37:208-12.

  16. Stella M, Cassano P, Bollero D, Clemente A. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001;203:45-9.

  17. Leyva L, Torres M J, Posadas S. Anticonvulsant-induced toxic epidermal necrolysis: monitoring the inmunologic response. J Allergy Clin Inmunol 2000; 105(1 Pt 1): 157-65.

  18. Egan CA, Grant WJ, Morris SE. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40: 458-61.

  19. Viard I, Wehrli P, Bullan R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998; 282:490-3.

  20. French. Inhibición de la necrólisis epidérmica tóxica con Ig G intravenosa humana. Act Terap Dermatol 2000; 23:369.

  21. Trent Jt, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the university of Miami experience. Arch Dermatol. 2003; 139:39-43.

  22. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens- Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139:33-6.

  23. Magina S, Lisboa C, Goncalves E, Conceicao F. A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br J Dermatol 2000; 142:191-2.

  24. Rutter A, Luger TA. High-dose intravenous immunoglobulin: an approach to treat severe immune-medíated and autoimmune disease of the skin. J Am Acad Dermatol. 2001; 44:1010-24.

  25. Dahl MV, Bridges Ag. Intravenous immune globulin: Fighting antibodies with antibodies. J Am Acad Dermatol. 2001; 45:775-83.

  26. Power WJ, Ghoraishi M; Merayo-Lloves J, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome / toxic epidermal necrolysis disease spectrum. Ophthalmology.1995; 102:1669-76.




2020     |     www.medigraphic.com